Chow J M, Moffatt J D, Cocks T M
Department of Pharmacology, Triradiate Building, The University of Melbourne, Victoria 3010, Australia.
Br J Pharmacol. 2000 Dec;131(8):1584-91. doi: 10.1038/sj.bjp.0703738.
Mechanisms of relaxation and contraction to protease-activated receptor- (PAR) tethered ligand peptides (SFLLRN/TFLLR, SLIGRL and GYPGKF (all C-terminally amidated) for PAR1, PAR2 and PAR4, respectively) and enzymes (thrombin and trypsin) were investigated in isolated segments of rat trachea, main and first order intrapulmonary bronchi. In airway segments previously exposed to SLIGRL, SFLLRN caused contractions that were potentiated by indomethacin, but were independent of mast cell degranulation. Contractions to TFLLR in the intrapulmonary bronchi were similarly potentiated by indomethacin. SLIGRL caused epithelium-dependent relaxations which were unaffected by N(G)-nitro-L-arginine, 1-H-oxodiazol-[1,2,4]-[4,3-a]quinoxaline-1-one or zinc-protoporphyrin-IX but were abolished by haemoglobin in all three regions of the airways. Relaxations to SLIGRL were markedly attenuated by indomethacin only in the main and intrapulmonary bronchi. GYPGKF caused epithelium-dependent relaxations in all three regions of the airway which were only significantly inhibited by indomethacin in the intrapulmonary bronchi. In general, thrombin and trypsin failed to cause any response in the airways tested. Intense PAR2-immunoreactivity was observed on airway epithelium. PAR1-immunoreactivity was faint on airway epithelium and smooth muscle, but was prevalent in mast cells. These findings indicate that PAR2 and possibly PAR4 present on rat airway epithelia mediate smooth muscle relaxation via cyclo-oxygenase-dependent and -independent mechanisms. PAR1-mediated contractions were most likely due to activation of smooth muscle receptors. The general failure of thrombin and trypsin to cause responses which may have been due to endogenous protease inhibitors, highlights the need for caution in assessing pathophysiological roles for PARs if only enzymes are used to activate PARs.
在大鼠气管、主支气管和一级肺内支气管的离体节段中,研究了蛋白酶激活受体-(PAR)系留配体肽(分别为PAR1的SFLLRN/TFLLR、PAR2的SLIGRL和PAR4的GYPGKF(均为C末端酰胺化))以及酶(凝血酶和胰蛋白酶)的舒张和收缩机制。在先前暴露于SLIGRL的气道节段中,SFLLRN引起收缩,吲哚美辛可增强这种收缩,但与肥大细胞脱颗粒无关。肺内支气管对TFLLR的收缩同样被吲哚美辛增强。SLIGRL引起上皮依赖性舒张,N(G)-硝基-L-精氨酸、1-H-恶二唑-[1,2,4]-[4,3-a]喹喔啉-1-酮或锌原卟啉-IX对其无影响,但在气道的所有三个区域中,血红蛋白可消除这种舒张。仅在主支气管和肺内支气管中,吲哚美辛可显著减弱对SLIGRL的舒张作用。GYPGKF在气道的所有三个区域中引起上皮依赖性舒张,仅在肺内支气管中,吲哚美辛可显著抑制这种舒张。一般来说,凝血酶和胰蛋白酶在测试的气道中未引起任何反应。在气道上皮上观察到强烈的PAR2免疫反应性。PAR1免疫反应性在气道上皮和平滑肌上较弱,但在肥大细胞中普遍存在。这些发现表明,大鼠气道上皮上存在的PAR2以及可能的PAR4通过环氧化酶依赖性和非依赖性机制介导平滑肌舒张。PAR1介导的收缩很可能是由于平滑肌受体的激活。凝血酶和胰蛋白酶一般未能引起反应,这可能是由于内源性蛋白酶抑制剂所致,这突出表明,如果仅使用酶来激活PARs,在评估PARs的病理生理作用时需要谨慎。